Akums Drugs & Pharmaceuticals
Mainboard₹1,857 Cr issue
+6.77%
Listing gain over issue price
Issue size
₹1,857 Cr
1 lot at cut-off
₹14,938
Lot size
22shares
Open
30 Jul 2024
Close
01 Aug 2024
Allotment
02 Aug 2024
Listing
06 Aug 2024
Listing performance
Issue price
₹679
Listed at
₹725
Listing-day close
₹796.35
Latest price
₹669
Close on 23 Oct 2026
Listing gain
+6.77%
Return since issue
-1.47%
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- IPO date
- 30 Jul 2024 – 01 Aug 2024
- Listing date
- 06 Aug 2024
- Face value
- ₹2 per share
- Issue price
- ₹679 per share
- Lot size
- 22 shares
- Total issue size
- ₹1,857 Cr
- Promoter holding
- 82.48% → 75.29% pre-issue → post-issue
- ISIN
- INE09XN01023
- Registrar
- MUFG Intime India Pvt.Ltd.
- Lead managers
- ICICI Securities Ltd.
- Registered office
- 304, Mohan Place, LSC Saraswati Vihar, New Delhi
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 1,22,05,912 | — | — |
| Market maker | 0 | — | — |
Application size
Minimum 22 shares per lot, in multiples, at ₹679
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 22 | ₹14,938 |
| Retail (max) | 13 | 286 | ₹1,94,194 |
| S-HNI (min) | 14 | 308 | ₹2,09,132 |
| S-HNI (max) | 66 | 1,452 | ₹9,85,908 |
| B-HNI (min) | 67 | 1,474 | ₹10,00,846 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Shares allocated
1,22,05,912
Anchor portion
₹829 Cr
at ₹679 per share
Valuation and performance
Valuation at offer price
₹679 per share
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | — | 0.05 |
| P/E (×) | — | 13,580.00 |
| Price to book (×) | 13.69 | — |
Key performance indicators
Latest reported period
- Return on net worth
- −0.57%
- ROCE
- 3.37%
- Debt / equity
- 0.69
- PAT margin
- 0.02%
- EBITDA margin
- 3.73%
- NAV per share
- ₹49.59
- Price to book
- 13.69
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Akums Drugs & Pharmaceuticals
Akums Drugs and Pharmaceuticals Limited is a public limited company incorporated on April 19, 2004, and is registered with Corporate Identity Number U24239DL2004PLC125888. The company operates as a pharmaceutical contract development and manufacturing organization (CDMO) offering comprehensive pharmaceutical products and services in India and internationally. Its business encompasses contract development and manufacturing services, the sale of branded pharmaceutical formulations, and the manufacturing of active pharmaceutical ingredients (APIs). Additional services include formulation research and development, preparation and filing of regulatory dossiers in Indian and global markets, and testing services. The company operates 12 manufacturing units (eight in Haridwar, Uttarakhand, one in Kotdwar, Uttarakhand, one in Baddi, Himachal Pradesh, and one each in Dera Bassi and Lalru, Punjab) and four R&D centres (two in Haridwar, one in Mumbai, one in Barwala). Several manufacturing units have been accredited by global regulatory agencies including European Good Manufacturing Practice, World Health Organization Good Manufacturing Practice, and the United States National Sanitation Foundation. The company generates revenue primarily from its CDMO business (78.18% of FY2024 revenue), followed by branded and generic formulations (16.74%) and APIs (5.09%). Revenue from operations grew from ₹36,718.93 million in FY2022 to ₹41,781.82 million in FY2024.
Company Analysis
from RHPAkums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization offering CDMO services, branded and generic formulations, and active pharmaceutical ingredients in India and overseas markets.
Akums Drugs and Pharmaceuticals Limited is a public limited company incorporated on April 19, 2004, and is registered with Corporate Identity Number U24239DL2004PLC125888. The company operates as a pharmaceutical contract development and manufacturing organization (CDMO) offering comprehensive pharmaceutical products and services in India and internationally. Its business encompasses contract development and manufacturing services, the sale of branded pharmaceutical formulations, and the manufacturing of active pharmaceutical ingredients (APIs). Additional services include formulation research and development, preparation and filing of regulatory dossiers in Indian and global markets, and testing services. The company operates 12 manufacturing units (eight in Haridwar, Uttarakhand, one in Kotdwar, Uttarakhand, one in Baddi, Himachal Pradesh, and one each in Dera Bassi and Lalru, Punjab) and four R&D centres (two in Haridwar, one in Mumbai, one in Barwala). Several manufacturing units have been accredited by global regulatory agencies including European Good Manufacturing Practice, World Health Organization Good Manufacturing Practice, and the United States National Sanitation Foundation. The company generates revenue primarily from its CDMO business (78.18% of FY2024 revenue), followed by branded and generic formulations (16.74%) and APIs (5.09%). Revenue from operations grew from ₹36,718.93 million in FY2022 to ₹41,781.82 million in FY2024.
Contract Development and Manufacturing Organization (CDMO)Branded pharmaceutical formulationsGeneric pharmaceutical formulationsActive Pharmaceutical Ingredients (API) manufacturing
Objects of the Issue
- Repayment/prepayment of all or certain borrowings of our Company 1,599.10 million p.26
- Repayment/prepayment of all or certain borrowings of our Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited 2,270.90 million p.26
- Funding incremental working capital requirements of our Company 550.00 million p.26
- Pursuing inorganic growth initiatives through acquisitions p.26
- General corporate purposes p.26
- Repayment/prepayment of indebtedness of our Company and its Subsidiaries p.78
- Funding incremental working capital requirements of our Company p.78
- Pursuing inorganic growth initiatives through acquisitions p.78
- General corporate purposes p.78
- Repayment/prepayment of all or certain borrowings of our Company ₹1,599.10 million p.125
- Repayment/prepayment of all or certain borrowings of our Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited ₹2,270.90 million p.125
- Funding incremental working capital requirements of our Company ₹550.00 million p.125
- Pursuing inorganic growth initiatives through acquisitions p.125
- General corporate purposes p.125
Issue Structure
- Total Issue
- Up to [●] Equity Shares of face value of ₹2 each aggregating up to ₹ [●] million
- Fresh Issue
- Up to [●] Equity Shares of face value of ₹2 each aggregating up to ₹6,800 million
- Offer for Sale
- Up to 17,330,435 Equity Shares of face value of ₹2 each aggregating up to ₹ [●] million by Selling Shareholders comprising: (i) Up to 1,512,000 Equity Shares aggregating up to ₹ [●] million by Sanjeev Jain; (ii) Up to 1,512,000 Equity Shares aggregating up to ₹ [●] million by Sandeep Jain; (iii) Up to 14,306,435 Equity Shares aggregating up to ₹ [●] million by Ruby QC Investment Holdings Pte. Ltd.
- Price Band
- The price band shall be decided by our Company in consultation with the Book Running Lead Managers and will be advertised in all editions of Financial Express and Jansatta at least two working days prior to the Bid/Offer Opening Date
- Lot Size
- [●] Equity Shares and in multiples of [●] Equity Shares thereafter
- Face Value
- ₹2 per Equity Share
Business Model
The company generates revenue through three primary segments: (1) Contract Development and Manufacturing Organization (CDMO) services, which comprises the majority of revenue at 78.18% of FY2024 total revenue of ₹41,781.82 million; (2) Branded and generic formulations representing 16.74% of revenue; and (3) Active Pharmaceutical Ingredients (APIs) representing 5.09% of revenue. The CDMO business operates under contracts typically ranging from two to five years with pharmaceutical companies, where the company manufactures products according to client specifications and regulatory requirements. The company procures raw materials according to client specifications, with 88.11% sourced domestically and 11.89% imported directly. The company does not maintain long-term contractual arrangements with suppliers but rather procures through purchase orders. Manufacturing operations are subject to extensive regulatory compliance and quality standards, with the company incurring sales returns of 2.69% of revenue in FY2024.
Business Segments
Provides contract development and manufacturing services to pharmaceutical companies for production of wide range of dosage forms under contracts typically ranging from two to five years, including procurement of raw materials according to client specifications and regulatory requirements
Sale of branded pharmaceutical formulations and generic formulations
Manufacturing of active pharmaceutical ingredients
Contract development and manufacturing of pharmaceutical products for external clients including tablets, capsules, injectables and other dosage forms; serves 1,524 clients as of March 31, 2024
Manufacturing of active pharmaceutical ingredients that are components of pharmaceutical formulations
Manufacturing and marketing of branded and generic pharmaceutical formulations domestically and internationally through subsidiaries Akumentis and Unosource; marketed in over 65 countries
Contract Development and Manufacturing Organization services for pharmaceutical clients
Manufacturing of Active Pharmaceutical Ingredients
Marketing and sale of branded and generic pharmaceutical formulations
Contract development and manufacturing of pharmaceutical formulations across 60+ dosage forms (tablets, capsules, liquid orals, vials, ampoules, sterile preparations, topicals, etc.); formulation R&D; regulatory dossier preparation; testing services; operates 10 manufacturing units with 49.23 billion units annual capacity; serves 1,524 clients including 26 of India's top 30 pharma companies
Marketing and sale of own branded formulations (over 140 brands) in India through Akumentis, with presence in gynaecology, cardiology, orthopaedics, paediatrics, dermatology; export of branded formulations to 65 countries through Unosource; marketing through distributors, own salesforce of 1,532 personnel in domestic market
Manufacturing and sale of active pharmaceutical ingredients; operates 3 manufacturing units with combined installed capacity of 737.384 MT annually (Dera Bassi, Lalru, Barwala); focuses on complex APIs and fermentation-based products
Through subsidiary Maxcure Nutravedics, manufactures nutraceuticals, food supplements, herbal and ayurvedic formulations, cosmetic and dermatological products; US NSF certified for quality and safety
Provides contract development and manufacturing services for pharmaceutical formulations including oral solids, oral liquids, injectables, topicals, and other dosage forms across various therapeutic areas
Markets and distributes branded and generic pharmaceutical formulations to end consumers and healthcare providers through subsidiary companies
Manufactures active pharmaceutical ingredients including beta-lactam range, general range of APIs, and high potent APIs (HPAPIs) for oncology and other specialized applications
Manufacturing and sale of pharmaceutical formulations (branded and generic) and active pharmaceutical ingredients
Manufacturing and sale of pharmaceutical formulations and active pharmaceutical ingredients
Trading of pharmaceutical formulations and related products
Contract manufacturing services for pharmaceutical products
Testing services and other charges related to pharmaceutical operations
Includes formulation research and development, preparation and regulatory filing of dossiers, manufacturing formulations on contract basis, job work and testing services
Engaged in manufacture and sale of KSM, Intermediate and API products
Engaged in marketing and distribution of branded and generic pharmaceutical formulations
Manufacturing and sale of pharmaceutical formulations including branded and generic products
Manufacturing and sales of APIs
SWOT Analysis
Strengths
- • Comprehensive CDMO service offering with multiple manufacturing units and R&D centers across India(p.25)
- • Global regulatory accreditations across manufacturing units(p.25)
- • Diversified product portfolio with strong CDMO revenue contribution(p.25)
- • Significant R&D capabilities with 927 approved formulations(p.41)
- • Strong revenue growth trajectory(p.27)
- • Diversified CDMO client base reducing concentration risk(p.51)
- • Strong recovery in EBITDA margin despite FY2024 challenges(p.54)
- • Significant international expansion with 65+ countries reached(p.59)
- • Substantial revenue growth from operations(p.51)
- • Largest India-focused CDMO with established scale and diverse client base(p.143)
- • Diversified product portfolio across CDMO, API, and Branded/Generic Formulations segments(p.145)
- • Strong R&D capabilities across product portfolio(p.143)
- • Strategic presence across pharmaceutical value chain(p.143)
- • Experienced management team with marquee PE investor backing(p.143)
- • Largest India-focused CDMO by revenue, capacity, and clients served(p.214)
- • Dominant market share in Indian domestic CDMO market(p.214)
- • Extensive manufacturing capacity across diverse dosage forms(p.214)
- • Strong regulatory compliance and accreditations(p.214)
- • Robust R&D capabilities with high regulatory approvals(p.216)
- • Large diverse client base with longstanding relationships(p.216)
- • Experienced management team with deep pharmaceutical expertise(p.219)
- • Strategic private equity backing from healthcare-focused investor(p.219)
- • Diverse dosage form manufacturing capabilities across 60+ formats(p.226)
- • Global regulatory certifications and multi-country approvals(p.226)
- • Proprietary in-house technology platforms for drug formulation(p.234)
- • Significant installed manufacturing capacity across CDMO and API segments(p.226)
- • Dedicated specialized manufacturing units for niche products(p.226)
- • Strong R&D infrastructure with 406 full-time scientists(p.234)
- • Robust quality control with 2,181 QA/QC personnel and accredited laboratories(p.235)
- • Established governance committee structure supporting operational oversight(p.277)
- • Experienced CFO with CA qualification and diversified financial sector background(p.284)
- • Qualified Company Secretary with specialized expertise in regulatory and patent law(p.284)
- • Significant non-current asset base supporting long-term operational capacity(p.302)
- • Strong revenue generation from pharmaceutical operations(p.303)
- • Leading India-focused CDMO with significant market share and capacity(p.397)
- • Extensive manufacturing capabilities across diverse dosage forms(p.397)
- • Strong relationships with leading pharmaceutical companies(p.399)
- • Low customer concentration in core CDMO business(p.400)
- • Significant R&D capability and innovation track record(p.401)
- • Growing and expanding client base(p.400)
Weaknesses
- • Geographic concentration of manufacturing and R&D facilities in Haridwar, Uttarakhand creates regional risk exposure(p.33)
- • Material regulatory and environmental compliance issues at subsidiary's API manufacturing unit in Punjab(p.45)
- • High capital expenditure requirements for maintaining and expanding operations(p.46)
- • Historical losses and volatile profitability(p.44)
- • Past corporate governance issues related to untraceable share transfer documentation(p.42)
- • Concentration of raw material suppliers within the business segments creates supply risk(p.36)
- • Heavy concentration of CDMO business in top 10 clients at ~39% of revenue(p.47)
- • Loss of major CDMO clients reducing business predictability(p.47)
- • Non-compliance history with covenant requirements in debt arrangements(p.49)
- • Environmental compliance violations with revocation of permits(p.57)
- • High employee attrition rate affecting operational continuity(p.69)
- • Substantial contingent liabilities from tax and regulatory matters(p.69)
- • Significant put option liability reflecting buyback obligation uncertainties(p.69)
- • Delays in payment of statutory dues including provident fund and GST(p.54)
- • Negative profitability in FY2024 with minimal profit after tax(p.145)
- • High debt-equity ratio of 0.69 times indicating moderate leverage(p.145)
- • API segment operating at significant loss with negative margin of -21.42%(p.145)
- • Low EBIT and PAT margins indicating operational inefficiency(p.145)
- • Corporate records and share transfer documents not fully traceable(p.36)
- • Historical non-compliance with Companies Act in preferential allotment of shares(p.32)
- • High customer concentration with top 10 clients representing 39% of CDMO revenue(p.216)
- • Significant decline in profitability in FY24(p.217)
- • Sharp deterioration in EBITDA margins from FY23 to FY24(p.217)
- • API business segment operating at significant losses(p.217)
- • Increasing debt-equity ratio indicating rising leverage(p.217)
- • Low capacity utilization at multiple manufacturing units(p.232)
- • Poor capacity utilization of recently commissioned units(p.232)
- • Historical delays in statutory payments(p.238)
- • Reliance on limited supplier base for raw materials(p.233)
- • High dependence on China for imported raw materials(p.233)
- • Significant reliance on promoter holdings creating concentration risk(p.287)
- • Conflicts of interest from promoter-related property transactions(p.289)
- • Negative profit attributable to equity holders despite revenue generation(p.303)
- • Substantial financial liabilities indicating leverage dependency(p.302)
- • High put option liability reflecting contingent payouts to non-controlling interests(p.304)
- • Put option liability creating financial obligation(p.328)
- • Large concentration of long-term debt with multiple borrowings(p.327)
- • Significant operating losses and declining profitability(p.335)
- • Substantial deferred tax asset dependent on future profitability(p.328)
- • Contingent liabilities from tax disputes and regulatory matters(p.337)
- • Increased sales returns indicating quality control challenges(p.401)
- • Significant financial leverage and put option liability(p.366)
- • Declining profitability with operational losses(p.415)
- • Declining revenues in branded and generic formulations segment(p.415)
- • Dependency on small group of raw material suppliers(p.402)
- • Significant regulatory litigations and compliance issues affecting operations(p.442)
- • Environmental compliance failures and plant shutdown risks at subsidiary(p.442)
- • High exposure to pharmaceutical pricing regulations and NPPA enforcement actions(p.426)
- • Multiple substandard product complaints affecting company reputation(p.424)
- • High dependence on subsidiary compliance with strict environmental regulations(p.434)
- • Company does not satisfy minimum operating profit threshold under SEBI regulations(p.455)
Opportunities
- • Growth in Indian pharmaceutical market driven by chronic disease prevalence and insurance penetration(p.25)
- • CDMO business expansion as pharmaceutical companies adopt asset-light models(p.25)
- • Strategic use of IPO proceeds for debt reduction and working capital enhancement(p.26)
- • Inorganic growth opportunities through acquisitions enabled by IPO proceeds(p.26)
- • Expansion of formulation approvals and pipeline development(p.41)
- • Expansion into international markets with growing pharmaceutical demand(p.59)
- • Strategic acquisitions to strengthen market position(p.66)
- • Increasing CDMO demand from regulated markets(p.56)
- • Growing client base diversification across multiple therapeutic areas(p.58)
- • Strong projected GDP growth in emerging markets, particularly India at 5.1% CAGR through 2027(p.163)
- • Geopolitical shift toward 'China plus one' strategy driving pharmaceutical manufacturing to India(p.163)
- • Planned debt reduction to improve debt-equity ratio and strengthen balance sheet(p.124)
- • Strategic acquisition targets to enhance scale and market position(p.138)
- • Expansion of working capital to support business growth(p.124)
- • Rapid growth in Indian domestic CDMO market projected at 14.3% CAGR(p.214)
- • Expansion into new therapeutic areas through domestic branded formulations(p.221)
- • Global expansion through international CDMO services(p.221)
- • Scaling API business with existing client relationships(p.221)
- • Growing demand for complex formulations and novel dosage forms(p.220)
- • Expansion into regulated and semi-regulated markets through export-oriented R&D(p.234)
- • Growth through novel dosage forms and drug delivery technologies(p.234)
- • Increased capacity utilization of newly acquired Baddi and expanded Haridwar facilities(p.238)
- • API business expansion with own manufacturing units(p.226)
- • Strategic focus on identifying and developing new pharmaceutical products(p.284)
- • ESG and sustainability initiatives to drive long-term stakeholder value(p.284)
- • Expansion of R&D capabilities with dedicated leadership and expertise(p.285)
- • Strong growth trajectory in Indian CDMO market(p.397)
- • Expansion of injectable manufacturing capacity(p.398)
- • Geographic expansion in emerging markets(p.400)
- • API manufacturing expansion and vertical integration(p.400)
- • Increased capacity utilization potential(p.399)
- • Expansion of API manufacturing capacity(p.420)
- • Growth in API business revenues(p.417)
Threats
- • Natural disasters in Himalayan region where operations are concentrated(p.33)
- • Regulatory changes and environmental policy shifts affecting operations(p.33)
- • Disruption in electrical power or water resources availability(p.34)
- • Dependence on imported raw materials from China and other countries(p.40)
- • Supply chain disruptions and commodity price volatility(p.36)
- • Quality control and manufacturing compliance risks affecting client relationships(p.34)
- • Client payment default risk affecting cash flows and profitability(p.46)
- • Intense competition in CDMO sector from larger competitors with greater resources(p.58)
- • Government price controls limiting revenue from regulated products(p.71)
- • Regulatory inspection and compliance risks affecting operations(p.57)
- • Foreign exchange volatility impacting international operations(p.61)
- • India's macroeconomic and geopolitical risks affecting operations(p.73)
- • Monsoon and natural disaster disruptions to manufacturing(p.48)
- • Product liability and regulatory action risks from sub-standard quality allegations(p.65)
- • Significant decline in EBITDA from ₹3,840.55 million in FY2023 to ₹1,570.10 million in FY2024(p.145)
- • Substantial outstanding debt of ₹4,915.55 million as of March 31, 2024(p.125)
- • Regulatory compliance risk from historical share allotment discrepancies requiring compounding(p.100)
- • Global pharmaceutical industry competition from established players(p.28)
- • Increasing regulatory stringency and compliance requirements globally(p.218)
- • Competition from global and regional CDMOs with established infrastructure(p.202)
- • Geopolitical tensions affecting supply chains and imports(p.202)
- • Pricing pressure reducing margins in generic pharmaceutical segment(p.180)
- • Heterogeneous regulatory compliance requirements across international markets(p.180)
- • Dependence on limited customer base for revenue concentration(p.232)
- • Supply chain disruptions from international raw material sourcing(p.233)
- • Regulatory changes in pharmaceutical pricing and import policies(p.241)
- • Intense competition from large pharmaceutical companies and other CDMOs(p.237)
- • Insurance coverage may be insufficient for operational hazards(p.236)
- • Hazards inherent in pharmaceutical manufacturing operations(p.236)
- • Significant fair value volatility in financial instruments creating P&L fluctuations(p.303)
- • Exposure to operating losses and variable profitability(p.303)
- • Flood-related operational losses impacting business continuity(p.305)
- • Significant finance costs reflecting borrowing burden(p.303)
- • Regulatory risk from pricing authority(p.338)
- • Export obligation compliance risk under EPCG scheme(p.338)
- • Historical income tax demand disputes(p.338)
- • Flood-related operational disruption and losses(p.335)
- • Exposure to foreign exchange risk from international operations(p.367)
- • Raw material price volatility and supply chain disruptions(p.402)
- • Reliance on imports for significant portion of raw materials(p.402)
- • Risk of regulatory and quality inspection failures(p.401)
- • High dependence on manufacturing operations continuity(p.399)
- • Regulatory enforcement over pharmaceutical pricing compliance(p.427)
- • Stringent environmental regulations and pollution control board enforcement(p.442)
- • Enforcement action by Directorate of Enforcement under PMLA(p.429)
- • Impact of regulatory actions on IEC and export operations(p.450)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Sanjeev Jain | Promoter/Promoter Selling Shareholder | 28,625,940 equity shares (19.43% including 33,000 shares held jointly with Arushi Jain) | — |
| Sandeep Jain | Promoter/Promoter Selling Shareholder | 28,639,690 equity shares (19.44% including 5,500 shares held jointly with Kanishk Jain and 5,500 shares held jointly with Manan Jain) | — |
| Akums Master Trust | Promoter | 64,200,000 equity shares (43.57% of pre-Offer equity share capital) | 64,200,000 equity shares |
| Sanjeev Jain | Promoter/Managing Director | — | — |
| Sandeep Jain | Promoter/Managing Director | — | — |
| Ruby QC Investment Holdings Pte. Ltd. | Investor/Promoter Group | — | — |
| Sanjeev Jain | Promoter | 19.43% | — |
| Sandeep Jain | Promoter | 19.44% | — |
| Akums Master Trust | Promoter | 43.57% | — |
| Ruby QC Investment Holdings Pte. Ltd. | Public | 14.65% | — |
| Sanjeev Jain | Promoter | — | — |
| Sandeep Jain | Promoter | — | — |
| Ruby QC Investment Holdings Pte. Ltd. | Promoter Group (backed by Quadria Capital) | — | 14.65% |
| Sanjeev Jain | Promoter | 19.43% | — |
| Sandeep Jain | Promoter | 19.44% | — |
| Sanjeev Jain | Promoter | 19.43% | — |
| Sandeep Jain | Promoter | 19.44% | — |
| Akums Master Trust | Promoter | 43.57% | — |
| Sanjeev Jain | Promoter | 42.42% | — |
| Sandeep Jain | Promoter | 42.45% | — |
| Ruby QC Investment Holding Pte Ltd. | Investor/Promoter Group | 15.09% | — |
| Sanjeev Jain | Promoter 1 | — | — |
| Sandeep Jain | Promoter 2 | — | — |
| Ruby QC Investment Holdings Pte. Ltd. | Investor | — | — |
Leadership
Sanjeev Jain · Managing Director/Promoter
Sandeep Jain · Promoter
Dharamvir Malik · Company Secretary and Compliance Officer
Sumeet Sood · Chief Financial Officer
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.
Akums Drugs & Pharmaceuticals IPO FAQs
What is the lot size of Akums Drugs & Pharmaceuticals IPO?
The minimum lot size of Akums Drugs & Pharmaceuticals IPO is 22 shares. One lot costs ₹14,938 at the cut-off price.
When does Akums Drugs & Pharmaceuticals IPO open and close?
Akums Drugs & Pharmaceuticals IPO opened for subscription on 30 Jul 2024 and closed on 01 Aug 2024.
What is the listing date of Akums Drugs & Pharmaceuticals IPO?
Akums Drugs & Pharmaceuticals IPO listed on 06 Aug 2024.